

20<sup>th</sup> July, 2023

- |   |  |
|---|--|
| <p>(1) BSE Limited<br/>Listing Department,<br/>Phiroze Jeejeebhoy Towers,<br/>Dalal Street,<br/>Mumbai 400 001</p> <p><b>Scrip Code: 500087</b></p> | <p>(2) National Stock Exchange of India Limited<br/>Listing Department<br/>Exchange Plaza, 5<sup>th</sup> floor,<br/>Plot no. C/1, G Block,<br/>Bandra Kurla Complex,<br/>Bandra (East), Mumbai - 400 051</p> <p><b>Scrip Code: CIPLA EQ</b></p> |
| <p>(3) SOCIETE DE LA BOURSE DE LUXEMBOURG<br/>Societe Anonyme<br/>35A Boulevard Joseph II,<br/>L-1840 Luxembourg</p>                                |  |

**Sub: Disclosure under Regulation 30 of the SEBI (Listing Obligations and Disclosure Requirements) Regulations, 2015.**

Dear Sir/Madam,

In furtherance to our earlier intimation dated 31<sup>st</sup> March, 2021, we wish to inform you that the National Company Law Tribunal, Mumbai vide its order dated 22<sup>nd</sup> June, 2023 (certified copy of which was received on 19<sup>th</sup> July 2023), has approved the Scheme of Amalgamation for merger of Pharmasofttech Awacs Private Limited into Pharmarack Technologies Private Limited. Both these companies are subsidiaries of Aarogya Bharat Digital LLP (earlier known as DigiHealth Technologies LLP), which in turn is a wholly-owned subsidiary of ABCD Technologies LLP.

The Company owns 6.45% interest in ABCD Technologies LLP.

This is for your information and records.

Thanking you,  
Yours faithfully,

**For Cipla Limited**

**Rajendra Chopra  
Company Secretary**